This study identifies MARCO as a key regulator of immunosuppression, fibrosis and tumor progression in iCCA, and supports its potential as a novel therapeutic target for macrophage-directed immunotherapy. This evidence concerns the gene MARCO and infantile convulsions and choreoathetosis.